XML 43 R33.htm IDEA: XBRL DOCUMENT v3.23.3
Stockholders' Equity (Tables)
9 Months Ended
Sep. 30, 2023
Stockholders' Equity Note [Abstract]  
Schedule of Stock Option Activity
The following table summarizes stock option activity during the nine months ended September 30, 2023:
SharesWeighted-
Average 
Exercise
Price
Weighted-
Average
Remaining
Contractual
Term
Aggregate
Intrinsic Value
(in thousands)(in years)(in thousands)
Outstanding at December 31, 20222,443 6.014.7$7,674 
Granted— — 
Exercised(265)7.59
Cancelled/forfeited(44)8.35 
Outstanding at September 30, 2023
2,134 5.774.0$28,657 
Vested and exercisable at September 30, 2023
2,129 5.753.9$28,627 
Schedule of RSU, PSU, MPSUs Activity
The following table summarizes RSU activity during the nine months ended September 30, 2023:
Number of SharesWeighted-Average 
Grant Date Fair Value Per Share
(in thousands)
Unvested RSUs as of December 31, 202211,990 $20.10 
Granted6,897 15.74 
Vested(5,306)19.01 
Cancelled/forfeited(1,280)22.61 
Unvested RSUs as of September 30, 2023
12,301 $17.86 
Number of SharesWeighted-Average Grant Date Fair Value Per Share
(in thousands)
Nonvested PSUs as of December 31, 2022267 $28.16 
Granted762 15.88 
Vested(78)28.16 
Cancelled/forfeited(122)28.16 
Nonvested PSUs as of September 30, 2023
829 $16.87 
Number of SharesWeighted-Average Grant Date Fair Value Per Share
(in thousands)
Nonvested MPSUs as of December 31, 20222,174 $6.80 
Granted87 7.25 
Vested— — 
Cancelled/forfeited(100)6.88 
Nonvested MPSUs as of September 30, 2023
2,161 $6.81 
Schedule of Stock-Based Compensation Expense
The following table summarizes the components of total stock-based compensation expense included in the accompanying condensed consolidated statements of operations:
Three months ended September 30,Nine months ended September 30,
2023202220232022
(in thousands)
Cost of revenue$2,860 $2,978 $8,378 $9,112 
Research and development12,122 14,488 35,808 46,966 
Sales and marketing9,061 10,920 25,643 31,198 
General and administrative11,670 10,992 31,027 27,102 
Total stock-based compensation expense$35,713 $39,378 $100,856 $114,378